Report Published: "Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023"

GlobalData has released its new PharmaPoint Drug Evaluation report, "Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023". HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third, and fourth-line metastatic.

Kadcyla (ado-trastuzumab) is Roche's third HER2-targeted mAb, approved by the FDA in February 2013, by the Japanese MHLW in September 2013, and by the EMA in November 2013, for the second-line treatment of metastatic HER2-positive breast cancer. Kadcyla is an antibody-drug conjugate consisting of trastuzumab covalently linked to the microtubule inhibitor, DM1 (mertansine) via a non-reducible thioether linkage (MCC).

Full Report Details at
- http://www.fastmr.com/prod/901472_kadcyla_her2positive_breast_cancer_forecast_and.aspx?afid=301

Scope

* Overview of HER2-Positive Breast Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on Kadcyla including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for Kadcyla for the top eight countries from 2013 to 2023.
* Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.

Reasons to Get this Report

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for HER2-Positive Breast Cancer
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of Kadcyla performance
* Obtain sales forecast for Kadcyla from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and China)

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- PharmaPoint: HER2-Positive Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023
- PharmaPoint: HER2-Positive Breast Cancer - US Drug Forecast and Market Analysis to 2023
- PharmaPoint: HER2-Positive Breast Cancer - China Drug Forecast and Market Analysis to 2023
- PharmaPoint: HER2-Positive Breast Cancer - Japan Drug Forecast and Market Analysis to 2023
- Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023